Former FDA Director Eric Karikari-Boateng joins Bio Usawa to lead its global regulatory strategy.

Bio Usawa, Inc., a leading biotechnology company committed to delivering affordable and accessible monoclonal antibody-based therapies for cancer, ophthalmic, autoimmune, and infectious diseases in Africa, has tapped the former Head of Laboratory Service at the Ghana’ Food and Drugs Authority, Eric Karikari-Boateng as its Head of Global Regulatory Strategy.

As Head of Global Regulatory Strategy, he will guide efforts to build next-generation regulatory capacity for ensuring timely approval and delivery of the biotech industry’s innovative, life-saving biotherapies.

Mr. Karikari-Boateng is a seasoned expert in regulatory affairs, pharmaceutical manufacturing, and quality assurance, with a proven ability to strengthen regulatory systems and enhance capacity across Africa. As the former Director of Laboratories at the Ghana Food and Drug Authority, he played pivotal roles as a senior assessor of biologics and small molecules, a GMP auditor, and a lead reviewer of clinical and non-clinical data. Notably, his leadership contributed to Ghana becoming the first country to approve the R21 malaria vaccine, marking a significant achievement in public health.

In addition to his work at the Ghana FDA, Mr. Karikari-Boateng has been an active participant in prominent regulatory initiatives such as the African Medicines Regulatory Harmonization project and the African Vaccine Regulation Forum, where he leads the Biologics Regulation Forum. His collaborations with global organizations, including the World Health Organization and the European Medicines Agency, have involved evaluating groundbreaking products like the RTS,S (Mosquirix) malaria vaccine and Pyramax, a malaria treatment.